NICE’s decision not to recommend olaparib for prostate cancer patients “disappointing”

Olaparib, a drug used to treat advanced prostate cancer patients, will not be made available on the NHS, after The National Institute for Health and Care Excellence (NICE) said the treatment was not cost-effective. NICE decided not to recommend the drug after an analysis found that the cost of olaparib (Lynparza) is higher than what NICE normally considers an acceptable use of NHS resources. Rose Gray, Head of Policy Development at Cancer Research UK, said the decisions will be “disappointing for people affected by [certain types of] advanced prostate cancer”, given that evidence has shown olaparib can give people more